Long-Term Outcomes of Birdshot Chorioretinopathy Treated with Corticosteroids: A Case Reports

• Published in: Journal of clinical medicine 2023-08, Vol.12 (16), p.5288
• Main Authors: Ferracci, Dino, Mathis, Thibaud, Gavoille, Antoine, Gerfaud-Valentin, Mathieu, Bert, Arthur, Hafidi, Meriem, Denis, Philippe, Loria, Olivier, Kodjikian, Laurent, Sève, Pascal
• Format: Article
• Language: English
• Subjects: Case reports; Case studies; Clinical medicine; Corticosteroids; Drug dosages; Drug therapy; Edema; Immunosuppressive agents; Inflammation; Medical imaging; Medical records; Patient outcomes; Patients; Performance evaluation; Retinal diseases; Steroids; Visual acuity; White people
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12165288

Purpose: To report the progression of patients diagnosed with birdshot chorioretinopathy (BSCR) initially treated with corticosteroids. Methods: We included 39 BSCR patients that were followed for ≥1 year. We analyzed their progression under treatment after 1, 3, 6 months, 1 year, and at the end of follow-up. In order to determine the efficiency of initial loading doses, patients were classified into two groups according to their initial treatment: methylprednisolone followed by prednisone (n = 28) and prednisone alone (n = 11). Results: At the end of follow-up, 31/39 (79.5%) patients had reached inflammation control. Thirteen out of 28 (46.4%) and 6/11 (54.5%) patients were treated exclusively with corticosteroids, and 18/19 (94.7%) of them had reached inflammation control at the end of follow-up; their mean (range) corticosteroid dose was 3.5 (0–10) mg/day. Conclusions: We found that the prolonged corticosteroid therapy treatment strategy resulted in inflammation control in half of BSCR patients. This control was maintained with low doses of cortisone, usually